Bayer says Xofigo/Xtandi combo shows overall survival benefit in prostate cancer
Source: SeekingAlpha
2026-02-26 14:36:15 ET
More on Bayer
- Bayer Aktiengesellschaft (BAYRY) Discusses Roundup Class Settlement Agreement and Implications for U.S. Glyphosate Litigation Transcript
- Bayer Aktiengesellschaft (BAYRY) Discusses OCEANIC-STROKE Phase III Results and Asundexian in Secondary Stroke Prevention - Slideshow
- Bayer Aktiengesellschaft (BAYRY) Discusses OCEANIC-STROKE Phase III Results and Asundexian in Secondary Stroke Prevention Transcript
- Bayer sues Johnson & Johnson over prostate cancer drug claims
- Bayer stumbles as investors question plan to settle Roundup litigation
Read the full article on Seeking Alpha
For further details see:
Bayer says Xofigo/Xtandi combo shows overall survival benefit in prostate cancer
Bayer AG ADR
NASDAQ: BAYRY
BAYRY Trading
8.01% G/L:
$11.53 Last:
121,220 Volume:
$11.43 Open:
BAYRY Latest News
March 04, 2026 08:00:00 am
New FDA 510(k) Clearance Expands Bayer's MEDRAD® MRXperion MR Injection System Support Across Diverse Range of MR Environments
BAYRY Stock Data
$53,660,545,583
3,929,696,328
N/A
7
N/A
Pharmaceuticals
Healthcare
DE
Leverkusen
